MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ASRT had $23,484K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$23,484K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Accounts receivable
    • Proceeds from maturities of shor...
    • Depreciation and amortization
    • Others
Negative Cash Flow Breakdown
    • Accrued rebates, returns and dis...
    • Net loss
    • Purchases of short-term investme...
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Impairment of intangible assets
-1,700 --
Loss on assertio therapeutics divestiture
-0 0 -8,174
Net loss
-18,856 -11,927 11,445 -29,893
Depreciation and amortization
5,840 5,839 5,630 18,536
Amortization of debt issuance costs
125 122 120 233
Impairment of intangible assets
--1,700 -
Accretion of interest income from short-term investments
-180 -49 -8 -36
Recurring fair value measurements of assets and liabilities
-30 167 302 -34
Payment of contingent consideration
-450 --
Provisions for inventory
198 1,313 522 2,675
Stock-based compensation
725 97 1,067 2,290
Accounts receivable
-58,583 -21,197 80,217 6,970
Inventories
-912 670 -7,595 -2,753
Prepaid and other assets
1,698 4,896 -14,017 7,912
Accounts payable and other accrued liabilities
196 -9,955 -10,351 7,014
Accrued rebates, returns and discounts
-37,022 -31,170 44,649 9,583
Interest payable
0 --650 -
Net cash provided by (used in) operating activities
8,563 -29,968 -4,767 6,553
Assertio therapeutics divestiture
-0 0 8,174
Proceeds from maturities of short-term investments
30,368 30,151 27,660 57,572
Purchases of short-term investments
15,258 28,452 31,472 59,273
Net cash provided by (used in) investing activities
15,110 1,699 -3,812 -9,875
Payments related to the vesting and settlement of equity awards
189 2 7 180
Net cash used in financing activities
-189 -2 -7 -180
Net increase (decrease) in cash and cash equivalents
23,484 -28,271 -8,586 -3,502
Cash and cash equivalents at beginning of year
10,229 38,500 50,588 -
Cash and cash equivalents at end of period
33,713 10,229 38,500 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof short-term...$30,368K Accounts receivable-$58,583K Depreciation andamortization$5,840K Inventories-$912K Stock-based compensation$725K Provisions for inventory$198K Accounts payable andother accrued...$196K Accretion of interestincome from short-term...-$180K Amortization of debt issuancecosts$125K Recurring fair valuemeasurements of assets and...-$30K Net cash provided by(used in) investing...$15,110K Net cash provided by(used in) operating...$8,563K Canceled cashflow$15,258K Canceled cashflow$58,226K Net increase(decrease) in cash and cash...$23,484K Canceled cashflow$189K Purchases of short-terminvestments$15,258K Accrued rebates,returns and discounts-$37,022K Net loss-$18,856K Prepaid and other assets$1,698K something is missing-$650K Net cash used infinancing activities-$189K Payments related to thevesting and settlement...$189K